Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
No Placebo
Drugs
Locations
Clinical Specialty
661-680 of 2,251 trials

Triple-Negative Breast Cancer: Keytruda with Chemotherapy

We are studying how different chemotherapy regimens combined with Keytruda affect the immune response in patients with early-stage triple-negative breast cancer. The goal is to find the most effective treatment approach for this specific cancer type.

Triple Negative Breast Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Coronary Artery Disease: Angiolite Stent and Antiplatelet Therapy Study

We are evaluating whether a new stent and a shorter antiplatelet therapy can reduce complications in patients with coronary artery disease. This study compares these approaches to standard treatment options.

Coronary Artery Disease>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteCardiology

Ovarian Stimulation in Older Women: INOVEE Study

We are comparing two doses of a fertility medication to see which produces more healthy embryos in older women undergoing fertility treatment. This study aims to improve outcomes for women trying to conceive.

Female Infertility3-6 monthsMonitoring phase (IV)No PlaceboStandard MedicinesEndocrinologyGynecology and Obstetrics

Long-Term Study on Gene-Modified Cell Treatments

We are evaluating the long-term health effects of gene-modified cells in participants, especially children and adolescents. This includes monitoring for serious side effects and overall growth and development.

Solid and Hematological Malignancies>2 yearsEfficacy phase (II)16-20 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteNeurologyOncologyRheumatology

Autoimmune Cytopenias: Povetacicept Study

We are testing a new treatment called povetacicept for individuals with autoimmune cytopenias. The study aims to evaluate its safety and effectiveness in managing this condition.

Autoimmune Cytopenias6-12 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementHematologyInfectious Diseases

Cirrhosis Treatment: Albumin and Enoxaparin Study

We are testing a new combination therapy of albumin and enoxaparin for patients with decompensated cirrhosis at high risk of complications. The study aims to assess safety and explore how this treatment may affect the disease.

Cirrhosis6-12 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesHepatologyInternal Medicine

Vitamin D Supplementation in Obese Children and Adolescents

We are comparing monthly versus daily vitamin D supplements to see which is more effective in raising vitamin D levels in obese children and teens. The study also looks at safety and how well participants follow the treatment.

Obesity in Children and Adolescents>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesEndocrinologyPediatrics

Pain Management in Laparoscopic Colorectal Surgery: Comparing Two Techniques

We are studying the effectiveness of two pain relief methods after laparoscopic colorectal surgery. Our goal is to find out which method reduces opioid use and improves recovery.

Patients Scheduled for Laparoscopic Colorectal Surgery1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesInternal MedicineOtolaryngology

Prostate Cancer: uPAR PET Imaging Study

We are investigating a new imaging method to help classify prostate cancer grades in men with localized, untreated disease. This study aims to assess the safety and effectiveness of this non-invasive technique.

Prostate Cancer≤3 monthsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesPartially RemoteOncologyOtolaryngology

Chronic Immune Thrombocytopenia: Kedrion IVIg Treatment

We are studying a new intravenous treatment for adults with chronic immune thrombocytopenia to see if it can increase platelet counts and reduce bleeding. This trial will help us understand how well this treatment works and its safety.

Chronic Immune Thrombocytopenia≤3 monthsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematology

Melanoma Treatment: Daromun Injection Study

We are studying whether intratumoral injections of Daromun can help patients with Stage IIIB/C melanoma live longer and reduce the chance of cancer returning after surgery. This trial compares the new treatment to standard surgery and therapy.

Stage III Superficial Spreading Melanoma>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementDermatologyOncology

Breast Cancer: Vepdegestrant and Samuraciclib Study

We are investigating the safety and effectiveness of a new oral medication combined with another treatment for adults with advanced or metastatic hormone receptor-positive breast cancer. This study aims to find better treatment options for patients facing this condition.

Advanced Breast CancerSafety phase (I)Efficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Labor Induction: Outpatient vs. Inpatient Methods

We are studying whether inducing labor at home is as safe and effective as doing it in a hospital. We want to understand the costs and experiences of women and healthcare staff in both settings.

Induction of Labour3-6 monthsMonitoring phase (IV)No PlaceboStandard MedicinesGynecology and Obstetrics

Non-Small Cell Lung Cancer: Divarasib with Other Therapies

We are studying the safety and effectiveness of divarasib combined with pembrolizumab and chemotherapy in patients with untreated advanced lung cancer that has a KRAS G12C mutation. This research aims to find the best dose and treatment approach.

Non-Small Cell Lung Cancer>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncologyPulmonology

Zilovertamab Vedotin for Pediatric Cancers

We are studying a new treatment for children and young adults with blood cancers and solid tumors. The trial aims to assess its safety and how well it may work in these young patients.

Blood Cancers and Solid Tumors>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesCost ReimbursementOncologyPediatrics

MECP2 Duplication Syndrome: ION440 Treatment Study

We are testing a new treatment called ION440 to see if it is safe and well-tolerated in patients with MECP2 Duplication Syndrome. This study will also look at how the drug moves through the body.

MECP2 Duplication SyndromeSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesHematology

Genitourinary Syndrome of Menopause: Cellular Matrix Treatment

We are studying a new treatment combining platelet-rich plasma and hyaluronic acid for women with genitourinary syndrome of menopause. This trial compares its effects to a standard estrogen gel to see which works better for symptom relief.

Genitourinary Syndrome of Menopause3-6 monthsMonitoring phase (IV)≤5 visitsNo PlaceboInvestigational MedicinesGynecology and Obstetrics

Atrial Fibrillation: Amiodarone Treatment Study

We are studying whether a longer or shorter course of amiodarone helps people with persistent atrial fibrillation return to a normal heart rhythm before a procedure. This may improve outcomes for patients undergoing electrical cardioversion.

Atrial Fibrillation1-2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesCardiology

Ruxolitinib Rollover Study for Cancer Patients

We are providing continued access to ruxolitinib for patients who have previously participated in related studies. The goal is to evaluate the safety of ruxolitinib alone or with other cancer treatments.

MyelofibrosisEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesHematologyOncology

Cervical Cancer: Fertility-Sparing Treatment Study

We are studying a new approach for women with early-stage cervical cancer to see if chemotherapy followed by surgery can help preserve fertility. This trial aims to evaluate the safety and effectiveness of this treatment method.

Cervical Cancer≤3 monthsEfficacy phase (II)No PlaceboStandard MedicinesGynecology and ObstetricsOncology